Likewise, in patients with cancer: (i) serum levels of soluble L1CAM are elevated in breast cancer and associate with poor prognosis [248]; (ii) a relationship has been also found between increased serum sL1CAM level and poor clinicopathological features in type 1 endometrial cancers [249]; and (iii) increased serum or plasma levels of sEng correlate with metastasis or poor survival in certain cancers, including colorectal carcinoma, prostate cancer, and myeloid malignancies [38, 93, 97]. Here, L1CAM is linked to cancer.